Pridopidine for ALS: Phase 3 trial testing safety and effectiveness
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial is testing if an oral medication called pridopidine can slow the progression of ALS. It is for people recently diagnosed with ALS who have mild to moderate breathing function and meet specific risk scores.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ALS (definite or probable based on standard criteria).
- Your first symptoms started within the last 18 months.
- Your breathing function (SVC) is at least 60% of what is expected for someone your age and size.
- Your risk score from a special ALS prediction calculator is between -6 and -2.
- You can swallow capsules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This Phase 2 study tests whether dazucorilant can slow or improve outcomes in people with amyotrophic lateral sclerosis (ALS) who are likely to progress more quickly. You may be able to join if you meet specific ALS type and risk-score requirements and your health tests and medications fit the study rules.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.